Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
25066675
DOI
10.1016/j.jsbmb.2014.07.007
PII: S0960-0760(14)00131-9
Knihovny.cz E-zdroje
- Klíčová slova
- 11β-hydroxysteroid dehydrogenase, Adipose tissue, Brain, Colon, Endocrine disruptor, Inhibitor, Placenta, Testis,
- MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 1 antagonisté a inhibitory metabolismus MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 2 antagonisté a inhibitory metabolismus MeSH
- diabetes mellitus chemicky indukované enzymologie patologie MeSH
- endokrinní disruptory farmakologie MeSH
- glukokortikoidy metabolismus MeSH
- inhibitory enzymů farmakologie MeSH
- kolon účinky léků enzymologie MeSH
- lidé MeSH
- metabolický syndrom chemicky indukované enzymologie patologie MeSH
- mozek účinky léků enzymologie MeSH
- nádory chemicky indukované enzymologie patologie MeSH
- obezita chemicky indukované enzymologie patologie MeSH
- orgánová specificita MeSH
- placenta účinky léků enzymologie MeSH
- těhotenství MeSH
- testis účinky léků enzymologie MeSH
- tuková tkáň účinky léků enzymologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- 11-beta-hydroxysteroiddehydrogenasa typ 1 MeSH
- 11-beta-hydroxysteroiddehydrogenasa typ 2 MeSH
- endokrinní disruptory MeSH
- glukokortikoidy MeSH
- inhibitory enzymů MeSH
Numerous chemicals in the environment have the ability to interact with the endocrine system. These compounds are called endocrine disruptors (EDs). Exposure to EDs represents one of the hypotheses for decreasing fertility, the increased risk of numerous cancers and obesity, metabolic syndrome and type 2 diabetes. There are various mechanisms of ED action, one of which is their interference in the action of 11β-hydroxysteroid dehydrogenase (11βHSD) that maintains a balance between active and inactive glucocorticoids on the intracellular level. This enzyme has two isoforms and is expressed in various tissues. Inhibition of 11βHSD in various tissues can have different consequences. In the case of EDs, the results of exposure are mainly adverse; on the other hand pharmaceutically developed inhibitors of 11βHSD type 1 are evaluated as an option for treating metabolic syndrome, as well as related diseases and depressive disorders. This review focuses on the effects of 11βHSD inhibitors in the testis, colon, adipose tissue, kidney, brain and placenta.
Citace poskytuje Crossref.org
